Senores Pharmaceuticals Limited has received a disclosure from promoter group entity Renosen Pharmaceuticals Private Limited regarding the release of pledge on 4,00,000 equity shares. The pledge was released on February 13, 2026, and disclosed to the stock exchanges on February 16, 2026, in compliance with SAST Regulations 31(1) and 31(2).

Pledge Release Details

The pledge release transaction involves the complete removal of encumbrance on the shares that were previously pledged as collateral to Bajaj Finance Limited:

Regulatory Compliance and Documentation

The disclosure was submitted to both BSE Limited (Scrip Code: 544319) and National Stock Exchange of India Limited (Symbol: SENORES) as mandated under SAST Regulations. Swapnil Jatinbhai Shah, serving as Director of Renosen Pharmaceuticals Private Limited with DIN 05259821, signed the disclosure documents on February 16, 2026.

Vinay Kumar Mishra, Company Secretary and Compliance Officer (ICSI Membership No.: F11464), submitted the formal disclosure on behalf of Senores Pharmaceuticals Limited to both stock exchanges.

Promoter Holdings Structure

The disclosure reveals the comprehensive shareholding pattern of promoters and promoter group entities in Senores Pharmaceuticals Limited:

Company Information

Renosen Pharmaceuticals Private Limited, formerly known as Senores Lifesciences Pvt. Ltd., holds a total of 27,08,719 shares in Senores Pharmaceuticals Limited, representing 5.88% of the total share capital. The company is registered with CIN U51909GJ2019PTC108258 and operates from Ahmedabad. The released pledge amount of 4,00,000 shares previously constituted encumbrance on the entity's holding, which has now been completely cleared.

Senores Pharmaceuticals Limited successfully concluded its Extra-Ordinary General Meeting (EGM) on January 31, 2026, securing shareholder approval for a significant capital raising initiative through convertible equity warrants. Following the successful EGM, the company has now submitted important amendments and clarifications to the original EGM notice under regulatory compliance requirements.

EGM Proceedings and Voting Results

The EGM was conducted at 12:30 P.M. through Video Conferencing (VC) and Other Audio-Visual Means (OAVM), with proceedings concluding at 12:55 P.M. The meeting addressed a single special resolution regarding the issuance of convertible equity warrants to the promoter and promoter group.

Warrant Issuance Approval

Shareholders overwhelmingly approved the special resolution for issuing 11,70,000 convertible equity warrants by way of preferential issue on private placement basis to persons belonging to the promoter and promoter group category. The resolution received strong support across all shareholder categories.

Regulatory Clarifications and Amendments

On February 04, 2026, Senores Pharmaceuticals submitted amendments and clarifications to Item No. 1 of the explanatory statement annexed to the EGM Notice dated January 07, 2026, under Regulation 30 of SEBI LODR Regulations. The company clarified that while the quantum of the proposed issue is less than 5% of the post-issue fully diluted share capital, making Regulation 166A of SEBI ICDR Regulations non-applicable, the company's Articles of Association require obtaining a valuation report from a registered valuer for determining the floor price.

Valuation Methodology

The registered valuer considered three valuation approaches: Asset Approach (Net Asset Value Method), Income Approach (Profit Earning Capacity Value Method), and Market Approach (Market Price Method). Since values calculated under the Profit Earning Capacity Value Method and Net Asset Value Method were less than the Market Price Method value, which also represents the Floor Price as per SEBI ICDR Regulations, the valuer assigned nil weightage to the first two methods and 100% weightage to the market approach.

Regulatory Compliance

Mukesh H. Shah & Co., Company Secretaries, served as the scrutinizer for the voting process, ensuring compliance with Section 108 of the Companies Act, 2013 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The clarification document was signed by Vinay Kumar Mishra, Company Secretary and Compliance Officer, and made available on the company's website and stock exchange platforms for stakeholder access.